Merck reported another Phase 3 win for its sacituzumab-based antibody-drug conjugate sac-TMT in gastric cancer, according to the latest company update. The result adds incremental momentum as the market continues to watch how Merck manages its broader oncology portfolio around future revenue shifts. In parallel, AbbVie struck a $2.54bn bispecific deal with DISCO Pharmaceuticals, giving AbbVie an option to exclusively license selected programs after DISCO completes research activities. The pact leverages DISCO’s surfaceome mapping and AND-gated bispecific concept designed to restrict binding to tumor cells expressing paired antigens. Together, the developments underscore a dual push in oncology: late-stage clinical validation for antibody-drug conjugates alongside continued financial commitment to next-generation precision oncology platforms.